ATE429432T1 - Indazolderivate als faktor xa-inhibitoren - Google Patents
Indazolderivate als faktor xa-inhibitorenInfo
- Publication number
- ATE429432T1 ATE429432T1 AT04731155T AT04731155T ATE429432T1 AT E429432 T1 ATE429432 T1 AT E429432T1 AT 04731155 T AT04731155 T AT 04731155T AT 04731155 T AT04731155 T AT 04731155T AT E429432 T1 ATE429432 T1 AT E429432T1
- Authority
- AT
- Austria
- Prior art keywords
- factor
- compounds
- formulae
- chem
- factor viia
- Prior art date
Links
- BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical class C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 title 1
- 229940123583 Factor Xa inhibitor Drugs 0.000 title 1
- 108010054265 Factor VIIa Proteins 0.000 abstract 4
- 108010074860 Factor Xa Proteins 0.000 abstract 4
- 150000001875 compounds Chemical class 0.000 abstract 4
- 229940012414 factor viia Drugs 0.000 abstract 4
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 208000001435 Thromboembolism Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000002785 anti-thrombosis Effects 0.000 abstract 1
- 230000023555 blood coagulation Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000005764 inhibitory process Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 230000002441 reversible effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03011303A EP1479675A1 (de) | 2003-05-19 | 2003-05-19 | Indazolderivate als Faktor Xa-Inhibitoren |
| PCT/EP2004/004753 WO2004101556A1 (en) | 2003-05-19 | 2004-05-05 | INDAZOLE-DERIVATIVES AS FACTOR Xa INHIBITORS |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE429432T1 true ATE429432T1 (de) | 2009-05-15 |
Family
ID=33040950
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT04731155T ATE429432T1 (de) | 2003-05-19 | 2004-05-05 | Indazolderivate als faktor xa-inhibitoren |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US7365088B2 (de) |
| EP (2) | EP1479675A1 (de) |
| JP (1) | JP4709763B2 (de) |
| AT (1) | ATE429432T1 (de) |
| AU (1) | AU2004238499A1 (de) |
| BR (1) | BRPI0410430A (de) |
| CA (1) | CA2528220A1 (de) |
| CL (1) | CL2004001080A1 (de) |
| DE (1) | DE602004020761D1 (de) |
| MX (1) | MXPA05012346A (de) |
| PE (1) | PE20050153A1 (de) |
| TW (1) | TW200510400A (de) |
| WO (1) | WO2004101556A1 (de) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1581503A4 (de) * | 2002-11-08 | 2007-07-25 | Merck & Co Inc | Ophthalmische zusammensetzungen zur behandlung der okularen hypertonie |
| US7358268B2 (en) * | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) * | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| US7223780B2 (en) * | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| EP1479677A1 (de) * | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Neue Indolderivate als Faktor Xa-Inhibitoren |
| US7494983B2 (en) * | 2003-09-04 | 2009-02-24 | Merck & Co. Inc. | Ophthalmic compositions for treating ocular hypertension |
| DE10342570A1 (de) * | 2003-09-15 | 2005-04-14 | Bayer Healthcare Ag | Verfahren zur Herstellung von 4-(4-Aminophenyl)-3-morpholinon |
| EP1568698A1 (de) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrolderivate als faktor-xa-inhibitoren |
| EP1571154A1 (de) * | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Derivate des Beta-Alanins als Hemmer des Faktors Xa |
| JP2007533745A (ja) * | 2004-04-20 | 2007-11-22 | アールエヌディー・ファーマシューティカルズ | 脂溶性のシリコン置換シクロオキシゲナーゼ−２選択的非ステロイド性抗炎症薬及び誘導体の医薬組成物及び使用方法 |
| DE102006030479A1 (de) * | 2006-07-01 | 2008-03-20 | Merck Patent Gmbh | Indazolderivate |
| DE102006032824A1 (de) * | 2006-07-14 | 2008-01-17 | Bayer Healthcare Ag | Substituierte Indazole |
| JO2701B1 (en) | 2006-12-21 | 2013-03-03 | جلاكسو جروب ليميتد | Vehicles |
| JP5389028B2 (ja) | 2007-08-14 | 2014-01-15 | コンサート ファーマシューティカルズ インコーポレイテッド | 置換オキサゾリジノン誘導体 |
| US8193182B2 (en) | 2008-01-04 | 2012-06-05 | Intellikine, Inc. | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
| BRPI0906473A8 (pt) | 2008-01-04 | 2016-02-10 | Intellikine Inc | Certas entidades químicas, composições e métodos |
| DE102008022221A1 (de) * | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
| US8541404B2 (en) * | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
| DE102010018299A1 (de) | 2010-04-23 | 2011-10-27 | Archimica Gmbh | Verfahren zur Herstellung von 4-(4-Aminophenyl)-morpholin-3-on |
| EP3238722B1 (de) | 2011-01-10 | 2019-03-13 | Infinity Pharmaceuticals, Inc. | Festen formen von isochinolinonen |
| MD4557C1 (ro) | 2011-05-06 | 2018-10-31 | Egis Gyogysszegyar Nyilvanosan Mukodo Reszvenytarsasag | Procedeu de obţinere a rivaroxabanului şi un compus intermediar utilizat în acest procedeu |
| US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
| RU2702908C2 (ru) | 2012-11-01 | 2019-10-14 | Инфинити Фармасьютикалз, Инк. | Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы |
| WO2015160975A2 (en) | 2014-04-16 | 2015-10-22 | Infinity Pharmaceuticals, Inc. | Combination therapies |
| EP3474856B1 (de) | 2016-06-24 | 2022-09-14 | Infinity Pharmaceuticals, Inc. | Kombinationstherapie |
| CN109456205B (zh) * | 2018-12-17 | 2021-09-21 | 石河子大学 | 以取代喹啉或异喹啉酰肼吡啶-n-氧化物为配体的水相体系中的n-芳基化方法 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5506134A (en) | 1990-10-22 | 1996-04-09 | Corvas International, Inc. | Hypridoma and monoclonal antibody which inhibits blood coagulation tissue factor/factor VIIa complex |
| US5788965A (en) | 1991-02-28 | 1998-08-04 | Novo Nordisk A/S | Modified factor VII |
| US5833982A (en) | 1991-02-28 | 1998-11-10 | Zymogenetics, Inc. | Modified factor VII |
| ZA953361B (en) | 1994-04-26 | 1996-01-12 | Selectide Corp | Factor Xa inhibitors |
| US5998424A (en) * | 1997-06-19 | 1999-12-07 | Dupont Pharmaceuticals Company | Inhibitors of factor Xa with a neutral P1 specificity group |
| US6339099B1 (en) * | 1997-06-20 | 2002-01-15 | Dupont Pharmaceuticals Company | Guanidine mimics as factor Xa inhibitors |
| EP0987274A1 (de) | 1998-09-15 | 2000-03-22 | Hoechst Marion Roussel Deutschland GmbH | Faktor VIIa Inhibitore |
| NZ511674A (en) * | 1998-12-23 | 2003-11-28 | Du Pont Pharm Co | Nitrogen containing heterobicycles as factor Xa inhibitors |
| KR20020087041A (ko) | 1999-07-28 | 2002-11-21 | 아벤티스 파마슈티칼스 프로덕츠 인크. | 치환된 옥소아자헤테로사이클릴 화합물 |
| DE10014645A1 (de) | 2000-03-24 | 2001-09-27 | Merck Patent Gmbh | Substituierte Biphenylderivate |
| AU2001268711A1 (en) * | 2000-06-23 | 2002-01-08 | Bristol-Myers Squibb Pharma Company | Heteroaryl-phenyl substituted factor xa inhibitors |
| EP1217000A1 (de) | 2000-12-23 | 2002-06-26 | Aventis Pharma Deutschland GmbH | Faktor Xa und Faktor VIIa Inhibitoren |
| CA2430978C (en) * | 2000-12-28 | 2012-05-15 | Daiichi Pharmaceutical Co., Ltd. | Vla-4 inhibitors |
| EP1314733A1 (de) | 2001-11-22 | 2003-05-28 | Aventis Pharma Deutschland GmbH | Indol-2-carbonsäureamide als Faktor-Xa-Hemmer |
| US7358268B2 (en) | 2002-12-04 | 2008-04-15 | Sanofi-Aventis Deutschland Gmbh | Imidazole derivatives as factor Xa inhibitors |
| US7429581B2 (en) | 2002-12-23 | 2008-09-30 | Sanofi-Aventis Deutschland Gmbh | Pyrazole-derivatives as factor Xa inhibitors |
| US7317027B2 (en) | 2003-05-19 | 2008-01-08 | Sanofi-Aventis Deutschland Gmbh | Azaindole-derivatives as factor Xa inhibitors |
| EP1479677A1 (de) | 2003-05-19 | 2004-11-24 | Aventis Pharma Deutschland GmbH | Neue Indolderivate als Faktor Xa-Inhibitoren |
| US7223780B2 (en) | 2003-05-19 | 2007-05-29 | Sanofi-Aventis Deutschland Gmbh | Triazole-derivatives as blood clotting enzyme factor Xa inhibitors |
| US7741341B2 (en) | 2003-05-19 | 2010-06-22 | Sanofi-Aventis Deutschland Gmbh | Benzimidazole-derivatives as factor Xa inhibitors |
| EP1568698A1 (de) | 2004-02-27 | 2005-08-31 | Aventis Pharma Deutschland GmbH | Pyrrolderivate als faktor-xa-inhibitoren |
| EP1571154A1 (de) | 2004-03-03 | 2005-09-07 | Aventis Pharma Deutschland GmbH | Derivate des Beta-Alanins als Hemmer des Faktors Xa |
-
2003
- 2003-05-19 EP EP03011303A patent/EP1479675A1/de not_active Withdrawn
-
2004
- 2004-05-05 MX MXPA05012346A patent/MXPA05012346A/es active IP Right Grant
- 2004-05-05 BR BRPI0410430-7A patent/BRPI0410430A/pt not_active IP Right Cessation
- 2004-05-05 AT AT04731155T patent/ATE429432T1/de not_active IP Right Cessation
- 2004-05-05 DE DE602004020761T patent/DE602004020761D1/de not_active Expired - Lifetime
- 2004-05-05 WO PCT/EP2004/004753 patent/WO2004101556A1/en not_active Ceased
- 2004-05-05 CA CA002528220A patent/CA2528220A1/en not_active Abandoned
- 2004-05-05 AU AU2004238499A patent/AU2004238499A1/en not_active Abandoned
- 2004-05-05 JP JP2006529742A patent/JP4709763B2/ja not_active Expired - Fee Related
- 2004-05-05 EP EP04731155A patent/EP1628972B1/de not_active Expired - Lifetime
- 2004-05-07 PE PE2004000474A patent/PE20050153A1/es not_active Application Discontinuation
- 2004-05-17 CL CL200401080A patent/CL2004001080A1/es unknown
- 2004-05-17 TW TW093113796A patent/TW200510400A/zh unknown
- 2004-05-19 US US10/849,088 patent/US7365088B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| WO2004101556A1 (en) | 2004-11-25 |
| BRPI0410430A (pt) | 2006-06-06 |
| TW200510400A (en) | 2005-03-16 |
| EP1628972A1 (de) | 2006-03-01 |
| PE20050153A1 (es) | 2005-04-25 |
| JP4709763B2 (ja) | 2011-06-22 |
| US20040235824A1 (en) | 2004-11-25 |
| EP1479675A1 (de) | 2004-11-24 |
| AU2004238499A1 (en) | 2004-11-25 |
| JP2006528942A (ja) | 2006-12-28 |
| CA2528220A1 (en) | 2004-11-25 |
| EP1628972B1 (de) | 2009-04-22 |
| MXPA05012346A (es) | 2006-05-25 |
| US7365088B2 (en) | 2008-04-29 |
| DE602004020761D1 (de) | 2009-06-04 |
| CL2004001080A1 (es) | 2005-04-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602004020761D1 (de) | INDAZOLDERIVATE ALS FAKTOR Xa-INHIBITOREN | |
| DE602004028367D1 (de) | Neue indolderivate als faktor xa-inhibitoren | |
| NO20032820D0 (no) | Oksybenzamidderivater som faktor XA inhibitorer | |
| MXPA04004797A (es) | Indol-2-carboxamidas como inhibidores del factor xa. | |
| TW200505914A (en) | Pyrazole-derivatives as factor Xa inhibitors | |
| WO2005085239A3 (en) | PYRROLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| NO20025810D0 (no) | Faktor VIIA-inhibitoriske (tio)ureaderivater, deres fremstilling og anvendelse | |
| DK1423357T3 (da) | Urinstofderivater med antiproteolytisk aktivitet | |
| DE60319711D1 (de) | Acylamino-substituierte heteroaromatische verbindungen und ihre verwendung als arzneimittel | |
| ATE394396T1 (de) | Triazolderivate als faktor-xa-inhibitoren | |
| TW200504027A (en) | Imidazole-derivatives as factor Xa inhibitors | |
| TW200503696A (en) | Benzimidazole-derivatives as factor Xa inhibitors | |
| TNSN05296A1 (en) | AZAINDOLE-DERIVATIVES AS FACTOR Xa INHIBITORS | |
| TW200716620A (en) | Heteroaryl-carboxylic acid (sulfamoyl alkyl) amide-derivatives as factor Xa inhibitors | |
| JO2467B1 (en) | New indole derivatives as an inhibitor of Xa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |